{"id":240455,"date":"2026-07-10T19:32:10","date_gmt":"2026-07-10T19:32:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-pa\/240455\/"},"modified":"2026-07-10T19:32:10","modified_gmt":"2026-07-10T19:32:10","slug":"feds-award-43-million-to-philly-gene-therapy-research-to-advance-treatments-for-rare-diseases","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-pa\/240455\/","title":{"rendered":"Feds award $43 million to Philly gene therapy research to advance treatments for rare diseases"},"content":{"rendered":"<p>Listen to article \u2022\u00a00:00 min<\/p>\n<p class=\"inq-p text-primary  \">The U.S. government has awarded Children\u2019s Hospital of Philadelphia $39 million to develop a scalable platform for treating rare genetic, liver-related diseases in infants and children.<\/p>\n<p class=\"inq-p text-primary  \">The federal Advanced Research Projects Agency for Health (ARPA-H) also <a class=\"relative z-1 text-blue-mid hover:shadow-lightmode\" data-link-type=\"article-body\" href=\"https:\/\/arpa-h.gov\/news-and-events\/arpa-h-awards-advance-personalized-curative-medicines-rare-genetic-diseases\" target=\"_blank\" rel=\"nofollow noopener\" title=\"https:\/\/arpa-h.gov\/news-and-events\/arpa-h-awards-advance-personalized-curative-medicines-rare-genetic-diseases\">announced this week<\/a> another $4 million for local gene therapy pioneer Jim Wilson to design gene therapies using AI at his <a class=\"relative z-1 text-blue-mid hover:shadow-lightmode\" data-link-type=\"article-body\" href=\"https:\/\/www.inquirer.com\/topic\/university-of-pennsylvania\" rel=\"nofollow noopener\" target=\"_blank\">University of Pennsylvania<\/a> spinout, GEMMABio.<\/p>\n<p class=\"inq-p text-primary  \">The $43 million in funding earmarked for Philadelphia researchers comes through a new federal effort to advance gene therapies for rare diseases. <\/p>\n<p class=\"inq-p text-primary  \">CHOP\u2019s team includes the duo behind last year\u2019s first-of-its-kind, personalized gene-editing treatment involving a Philadelphia-area infant, known as Baby KJ. CHOP\u2019s Rebecca Ahrens-Nicklas and Penn Medicine\u2019s Kiran Musunuru together created a custom drug to correct the genetic mutation driving Baby KJ\u2019s rare metabolic disease \u2014 dramatically improving his liver function. <\/p>\n<p class=\"inq-p type-interstitial text-primary\">\u00bb READ MORE: <a target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-link-type=\"interstitial\" href=\"https:\/\/www.inquirer.com\/health\/childrens-hospital-penn-treatment-cps1-deficiency-20250515.html\" class=\"no-underline text-blue-mid hover:shadow-lightmode\">CHOP and Penn treated an infant with a rare disease by editing his genes<\/a><\/p>\n<p class=\"inq-p text-primary  \">The funding will expand their work and bring in another CHOP researcher, Lindsey George, who develops gene therapies for bleeding disorders. <\/p>\n<p class=\"inq-p text-primary  \">\u201cWe\u2019re trying to move beyond just one diagnosis or one gene,\u201d Ahrens-Nicklas said.<\/p>\n<p class=\"inq-p text-primary  \">Philly-based scientists comprise two of seven research teams nationwide to receive funding through ARPA-H\u2019s new $160 million effort.<\/p>\n<p class=\"inq-p text-primary  \"><a class=\"relative z-1 text-blue-mid hover:shadow-lightmode\" data-link-type=\"article-body\" href=\"https:\/\/arpa-h.gov\/explore-funding\/programs\/thrive\" target=\"_blank\" rel=\"nofollow noopener\" title=\"https:\/\/arpa-h.gov\/explore-funding\/programs\/thrive\">Called THRIVE, the program aims<\/a> to help the roughly one in 10 people \u2014 most being newborns, infants, and children \u2014 with chronic genetic diseases. Ninety-five percent of rare diseases have no approved treatments.<\/p>\n<p class=\"inq-p text-primary  \">Leaders want to develop \u201cprecision genetic medicines through platforms that can test multiple treatments for multiple diseases in a single clinical trial,\u201d ARPA-H director Alicia Jackson said in a Thursday news release.<\/p>\n<p class=\"inq-p type-interstitial text-primary\">\u00bb READ MORE: <a target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-link-type=\"interstitial\" href=\"https:\/\/www.inquirer.com\/health\/linneaus-therapeutics-arpah-aging-melanoma-20260316.html\" class=\"no-underline text-blue-mid hover:shadow-lightmode\">Feds award $22 million to Penn spinout Linnaeus Therapeutics to advance anti-aging drug<\/a><\/p>\n<p>CHOP\u2019s expanding focus<\/p>\n<p class=\"inq-p text-primary  \">The CHOP team will focus on building a scalable gene-editing platform that can be used to treat a variety of infants and children.<\/p>\n<p class=\"inq-p text-primary  \">Their initial focus is on liver-related genetic diseases, ranging from urea cycle disorders to blood clotting diseases.<\/p>\n<p class=\"inq-p text-primary  \">\u201cEssentially it\u2019s the same drug, whether or not you\u2019re targeting a genetic variant that causes a rare metabolic disease or a genetic variant that causes a rare coagulation disorder,\u201d Ahrens-Nicklas said.<\/p>\n<p class=\"inq-p text-primary  \">Their five-year plan includes launching preclinical and clinical trials testing the safety and efficacy of their individualized treatments.<\/p>\n<p class=\"inq-p text-primary  \">They will also pursue regulatory approvals, work with payors, and implement their therapies at community sites and remote hubs to expand access.<\/p>\n<p class=\"inq-p text-primary  \">\u201cWe are the three musketeers that already text 25,000 times a day, and will continue to do so,\u201d Ahrens-Nicklas said. <\/p>\n<p>Wilson experimenting with AI<\/p>\n<p class=\"inq-p text-primary  \">Wilson founded academia\u2019s first gene therapy program back in 1993 as a professor at Penn.<\/p>\n<p class=\"inq-p text-primary  \">He left in 2024 to spin out biotech start-ups dedicated to tackling rare diseases with genetic medicines.<\/p>\n<p class=\"inq-p type-interstitial text-primary\">\u00bb READ MORE: <a target=\"_blank\" rel=\"noopener noreferrer nofollow\" data-link-type=\"interstitial\" href=\"https:\/\/www.inquirer.com\/health\/james-wilson-gemma-biotherapeutics-gene-therapy-20250527.html\" class=\"no-underline text-blue-mid hover:shadow-lightmode\">Geneticist Jim Wilson left UPenn behind, but not his dream of curing rare genetic diseases<\/a><\/p>\n<p class=\"inq-p text-primary  \">\u201cThe question is, can we find ways to scale this bespoke personalized medicine strategy, so that it is affordable and cost-effective?\u201d he said.<\/p>\n<p class=\"inq-p text-primary  \">In partnership with a biotech called ProFluent, GEMMABio will use AI to design its base editors \u2014 the machinery that goes in and make edits to DNA. <\/p>\n<p class=\"inq-p text-primary  \">The tool could be rapidly adapted to different patients and diseases, theoretically making the process more affordable, scalable, and efficient, Wilson said.<\/p>\n<p class=\"inq-p text-primary  \">His $4 million award will fund preclinical studies of their technology. <\/p>\n<p class=\"inq-p text-primary  \">GEMMABio\u2019s initial focus is on two rare liver diseases \u201cfor which there is significant unmet need,\u201d he said, including Maple Syrup Urine Disease and homozygous familial hypercholesterolemia (HoFH).<\/p>\n","protected":false},"excerpt":{"rendered":"Listen to article \u2022\u00a00:00 min The U.S. government has awarded Children\u2019s Hospital of Philadelphia $39 million to develop&hellip;\n","protected":false},"author":2,"featured_media":75914,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[69,71,70,103344],"class_list":["post-240455","post","type-post","status-publish","format-standard","has-post-thumbnail","category-philadelphia","tag-philadelphia","tag-philadelphia-headlines","tag-philadelphia-news","tag-philadelphia-gene-therapy-research-federal-government-funding-rare-disease-treatment"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts\/240455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/comments?post=240455"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts\/240455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/media\/75914"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/media?parent=240455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/categories?post=240455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/tags?post=240455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}